GlaxoSmithKline AIP for Consumer Healthcare

RSCA/W

Version:

Item Number: 11000000009099

Manufacturing Site: GSK-ESP-Alcala-ESALC

Market or Pack Owner:

CH-United Kingdom-GBR; CH-UK Regulatory-GBR

Market Trade Name: ENO

No. of Colours: 3

(does NOT include Varnish, if applicable)

List Colours:

(include sample in fields provided below; e g. spot / spot-CMYK equivalent)

286    185 White

ro

00

c

s

E

E

What Eno does....    .......

Eno provides effective relief from indigestion, flatulence and nausea. Eno contains three active ingredients sodium bicarbonate, citric add and anhydrous sodium carbonate which react in a glass of water to produce a formula that neutralises stomach acid, bringing the system back to normal.

Check before you take Eno

Do not take Eno:

•    if you have ever had an allergic reaction to sodium bicarbonate, sodium carbonate, citric acid, or any other ingredient in this product.

•    if you are on a controlled sodium diet Each 5 g dose contains 0.85 g of sodium

•    jfyou have any liver or kidney problems

•    for more than 14 days

•    if you are under 12 years unless your doctor tells you to.

Talk to your doctor

•    if your symptoms persist or worsen

•    if you are pregnant or breast feeding

•    if you are taking other medicines.

How to take Eno

Dissolve the powder in a glass of water before taking it. Adults and children 12 years and over: Take 5 g (one 5 ml spoonful) in a glass of water. Use when symptoms occur. A second dose may be taken after 2-3 hours.

Do not take the second dose less than 2 hours after the first dose. Do not take more than two times a day.

Do not exceed the stated dose.

Possible side effects

Like all medicines, Eno can have side effects, but not everyone gets them. Stomach irritations causing wind or bloating can occur. In the event of overdose seek medical advice. If you do get any side effects, tell your doctor or pharmacist.

How to store Eno

Keep out of the reach and sight of : children. Do not use this medicine after: the 'EXP' date shown on the pack.

GlaxoSmithKline Anhydrous Sodium Carbonate 0.50 g.

The marketing    This pack contains 150 q

authorisation holder is

GlaxoSmithKline Consumer Healthcare,

Brentford, TW8 9G5, U.K. and all enquiries should be sent to this address.

The manufacturer is Smith Kline Beecham SA,

28806 Alcala de Henares, Madrid, Spain.

This information was last revised inuanuary 20T21 ENO is a registered trade mark of the 1 C/\ ft GlaxoSmithKline group of companies. I Jv (J

Further information

Active ingredient Each 5 g of Eno powder contains Sodium Bicarbonate 2.32 g.

Citric Acid 2.18 g and

F508001/04 11000000009099 PL 00079/0273

Pharmacode Ref no is 578

Colour Standard Reference Number: N/A

FOR CONTENT ONLY

Please refer to existing colour standard.

GlaxoSmithKline

Technical Reference No(s).: F508D001

(do NOT include the technical reference doc[s] version no[s].)

Artwork copyright is the property of the GlaxoSmithKline Group of Companies

All suppliers providing a service to GSK for printed components of any description must ensure that they have a licence for all fonts / software used in conjunction with GSK artwork.

The distribution and use of fonts / software without a licence constitutes an intellectual property infringement. GSK will not accept any liability for the breach of third party intellectual property rights by printed component suppliers.

The GSK certification / audit process requires suppliers to declare that they do not use unlicensed fonts / software and may require the supplier to produce evidence of such licence to GSK.

o

□

IMPORTANT

ATTENTION • ATTENTION

To Ensure Accurate PDF Viewing and Printing: FOR SCREEN VIEWING: Use Adobe Acrobat 5 Professional or Adobe Acrobat Reader, Standard or Professional (higher than 5). Overprint Preview must be activated for accurate on screen viewing. FOR PRINTING: Use only Acrobat Professional version 5 or higher. "Apply Overprint Preview" or "Simulate Overprinting" must be activated in the print settings for printing accurate hard copies.

GSK Market is responsible for this product, its design and content.

Ensure the artwork is thoroughly checked, all the text proof-read and approved.

RSC GSK is responsible for site technical requirements and pre-press suitability.

GSK Market

is responsible to advise RSC in case changes required impact the followings:

Formulation Tablet embossing Storage conditions Shelf Life

BHE

ENO

Only Braille text, will not be printed

The Market is fully responsible for the approval and certification of the Braille translation and content.

GlaxoSmithKline AIP for Consumer Healthcare

RSCA/W

Version:

Item Number: 11000000009099

Manufacturing Site: GSK-ESP-Alcala-ESALC

Market or Pack Owner:

CH-United Kingdom-GBR; CH-UK Regulatory-GBR

Market Trade Name: ENO

No. of Colours: 3

(does NOT include Varnish, if applicable)

List Colours:

(include sample in fields provided below; e g. spot / spot-CMYK equivalent)

286    185 White

ro

00

c

s

E

E

Pharmacode Ref no is 578

Colour Standard Reference Number: N/A

FOR CONTENT ONLY

Please refer to existing colour standard.

GlaxoSmithKline

Technical Reference No(s).: F508D001

(do NOT include the technical reference doc[s] version no[s].)

Artwork copyright is the property of the GlaxoSmithKline Group of Companies

All suppliers providing a service to GSK for printed components of any description must ensure that they have a licence for all fonts / software used in conjunction with GSK artwork.

The distribution and use of fonts / software without a licence constitutes an intellectual property infringement. GSK will not accept any liability for the breach of third party intellectual property rights by printed component suppliers.

The GSK certification / audit process requires suppliers to declare that they do not use unlicensed fonts / software and may require the supplier to produce evidence of such licence to GSK.

o

□

IMPORTANT

ATTENTION • ATTENTION

To Ensure Accurate PDF Viewing and Printing: FOR SCREEN VIEWING: Use Adobe Acrobat 5 Professional or Adobe Acrobat Reader, Standard or Professional (higher than 5). Overprint Preview must be activated for accurate on screen viewing. FOR PRINTING: Use only Acrobat Professional version 5 or higher. "Apply Overprint Preview" or "Simulate Overprinting" must be activated in the print settings for printing accurate hard copies.

GSK Market is responsible for this product, its design and content.

Ensure the artwork is thoroughly checked, all the text proof-read and approved.

RSC GSK is responsible for site technical requirements and pre-press suitability.

GSK Market

is responsible to advise RSC in case changes required impact the followings:

Formulation Tablet embossing Storage conditions Shelf Life

BHE

ENO

Only Braille text, will not be printed

The Market is fully responsible for the approval and certification of the Braille translation and content.

GlaxoSmithKline AIP for Consumer Healthcare

RSCA/W

Version:

Item Number: 11000000009099

Manufacturing Site: GSK-ESP-Alcala-ESALC

Market or Pack Owner:

CH-United Kingdom-GBR; CH-UK Regulatory-GBR

Market Trade Name: ENO

No. of Colours: 3

(does NOT include Varnish, if applicable)

List Colours:

(include sample in fields provided below; e g. spot / spot-CMYK equivalent)

286    185 White

ro

00

c

s

E

E

Pharmacode Ref no is 578

Colour Standard Reference Number: N/A

FOR CONTENT ONLY

Please refer to existing colour standard.

GlaxoSmithKline

Technical Reference No(s).: F508D001

(do NOT include the technical reference doc[s] version no[s].)

Artwork copyright is the property of the GlaxoSmithKline Group of Companies

All suppliers providing a service to GSK for printed components of any description must ensure that they have a licence for all fonts / software used in conjunction with GSK artwork.

The distribution and use of fonts / software without a licence constitutes an intellectual property infringement. GSK will not accept any liability for the breach of third party intellectual property rights by printed component suppliers.

The GSK certification / audit process requires suppliers to declare that they do not use unlicensed fonts / software and may require the supplier to produce evidence of such licence to GSK.

o

□

IMPORTANT

ATTENTION • ATTENTION

To Ensure Accurate PDF Viewing and Printing: FOR SCREEN VIEWING: Use Adobe Acrobat 5 Professional or Adobe Acrobat Reader, Standard or Professional (higher than 5). Overprint Preview must be activated for accurate on screen viewing. FOR PRINTING: Use only Acrobat Professional version 5 or higher. "Apply Overprint Preview" or "Simulate Overprinting" must be activated in the print settings for printing accurate hard copies.

GSK Market is responsible for this product, its design and content.

Ensure the artwork is thoroughly checked, all the text proof-read and approved.

RSC GSK is responsible for site technical requirements and pre-press suitability.

GSK Market

is responsible to advise RSC in case changes required impact the followings:

Formulation Tablet embossing Storage conditions Shelf Life

BHE

ENO

Only Braille text, will not be printed

The Market is fully responsible for the approval and certification of the Braille translation and content.